Biodexa Pharmaceuticals (BDRX) Retained Earnings (2013 - 2025)

Biodexa Pharmaceuticals has disclosed Retained Earnings across 13 years of filings, most recently posting -$207.3 million for Q4 2025.

• In Q4 2025, Retained Earnings fell 7.35% year-over-year to -$207.3 million; the TTM figure through Dec 2025 stood at -$207.3 million (down 7.35% YoY), while the FY2025 annual figure was -$205.4 million, down 6.84% from the prior year.
• Retained Earnings came in at -$207.3 million for Q4 2025 at Biodexa Pharmaceuticals, down from -$205.6 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$158.7 million in Q4 2022 to a low of -$207.3 million in Q4 2025.
• Average Retained Earnings over 5 years is -$181.7 million, with a median of -$177.6 million recorded in 2023.
• Year-over-year, Retained Earnings declined 20.04% in 2021 and gained 7.86% in 2022.
• Over 5 years, Retained Earnings stood at -$172.3 million in 2021, then grew by 7.86% to -$158.7 million in 2022, then declined by 13.19% to -$179.7 million in 2023, then decreased by 7.45% to -$193.1 million in 2024, then retreated by 7.35% to -$207.3 million in 2025.
• Per Business Quant data, the three most recent Retained Earnings figures were -$207.3 million in Q4 2025, -$205.6 million in Q2 2025, and -$193.1 million in Q4 2024.